 Laura Saba
Concepts (573)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcohol Drinking | 18 | 2021 | 652 | 2.330 |
Why?
| | Quantitative Trait Loci | 24 | 2022 | 324 | 2.000 |
Why?
| | Gene Regulatory Networks | 7 | 2023 | 239 | 1.480 |
Why?
| | Ethanol | 15 | 2020 | 575 | 1.380 |
Why?
| | Transcriptome | 8 | 2022 | 756 | 1.330 |
Why?
| | Brain | 19 | 2023 | 2490 | 1.170 |
Why?
| | Quantitative Trait, Heritable | 7 | 2017 | 119 | 1.150 |
Why?
| | Gene Expression Profiling | 16 | 2021 | 1597 | 1.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2021 | 453 | 1.070 |
Why?
| | Rats, Inbred Strains | 7 | 2019 | 394 | 1.040 |
Why?
| | Systems Biology | 3 | 2021 | 57 | 1.010 |
Why?
| | Liver | 9 | 2019 | 1816 | 0.870 |
Why?
| | Adrenocortical Carcinoma | 5 | 2023 | 47 | 0.870 |
Why?
| | Genetic Predisposition to Disease | 12 | 2018 | 2275 | 0.850 |
Why?
| | MicroRNAs | 6 | 2019 | 637 | 0.810 |
Why?
| | Sequence Analysis, RNA | 7 | 2022 | 409 | 0.790 |
Why?
| | RNA | 6 | 2021 | 833 | 0.770 |
Why?
| | Phenotype | 15 | 2020 | 3003 | 0.770 |
Why?
| | Polyadenylation | 1 | 2021 | 38 | 0.760 |
Why?
| | Protein Carbonylation | 7 | 2019 | 52 | 0.750 |
Why?
| | Mitotane | 5 | 2023 | 6 | 0.750 |
Why?
| | Rats | 18 | 2023 | 5392 | 0.740 |
Why?
| | RNA, Long Noncoding | 2 | 2020 | 161 | 0.740 |
Why?
| | Polymorphism, Single Nucleotide | 17 | 2022 | 2062 | 0.740 |
Why?
| | Adrenal Cortex Neoplasms | 4 | 2023 | 48 | 0.720 |
Why?
| | Drug Tolerance | 4 | 2020 | 78 | 0.670 |
Why?
| | Animals | 54 | 2024 | 33381 | 0.670 |
Why?
| | Software | 7 | 2019 | 613 | 0.670 |
Why?
| | Tunica Media | 1 | 2018 | 36 | 0.640 |
Why?
| | Tunica Intima | 1 | 2018 | 78 | 0.620 |
Why?
| | Carotid Stenosis | 1 | 2018 | 75 | 0.600 |
Why?
| | Databases, Genetic | 5 | 2017 | 253 | 0.600 |
Why?
| | Alcohol-Related Disorders | 1 | 2018 | 111 | 0.600 |
Why?
| | Genetic Variation | 4 | 2019 | 926 | 0.570 |
Why?
| | Carotid Arteries | 1 | 2018 | 184 | 0.570 |
Why?
| | Alcoholism | 8 | 2021 | 717 | 0.550 |
Why?
| | Complement C3 | 4 | 2021 | 192 | 0.540 |
Why?
| | Central Nervous System Depressants | 4 | 2010 | 89 | 0.520 |
Why?
| | Models, Statistical | 1 | 2018 | 636 | 0.490 |
Why?
| | Liver Diseases, Alcoholic | 4 | 2019 | 87 | 0.490 |
Why?
| | Internet | 6 | 2010 | 633 | 0.470 |
Why?
| | Bayes Theorem | 5 | 2020 | 344 | 0.450 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2019 | 770 | 0.440 |
Why?
| | Mice | 31 | 2022 | 15520 | 0.410 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2023 | 143 | 0.400 |
Why?
| | Genomics | 5 | 2018 | 706 | 0.390 |
Why?
| | Aldehydes | 5 | 2019 | 154 | 0.380 |
Why?
| | Glutathione Transferase | 4 | 2019 | 97 | 0.380 |
Why?
| | Mice, Inbred Strains | 9 | 2020 | 405 | 0.370 |
Why?
| | Health Education | 3 | 2008 | 318 | 0.360 |
Why?
| | Male | 57 | 2021 | 57801 | 0.350 |
Why?
| | Rats, Wistar | 3 | 2020 | 399 | 0.340 |
Why?
| | Synaptic Transmission | 1 | 2010 | 239 | 0.330 |
Why?
| | Genetic Association Studies | 5 | 2017 | 371 | 0.330 |
Why?
| | Tandem Mass Spectrometry | 5 | 2024 | 421 | 0.310 |
Why?
| | Point Mutation | 2 | 2001 | 228 | 0.290 |
Why?
| | beta-Thalassemia | 4 | 2013 | 23 | 0.290 |
Why?
| | Humans | 68 | 2023 | 118972 | 0.290 |
Why?
| | Genes, Regulator | 1 | 2006 | 33 | 0.290 |
Why?
| | PTEN Phosphohydrolase | 2 | 2018 | 143 | 0.280 |
Why?
| | Adenylyl Cyclases | 3 | 2012 | 86 | 0.270 |
Why?
| | Smoking Prevention | 1 | 2006 | 150 | 0.270 |
Why?
| | Oxidative Stress | 4 | 2019 | 1178 | 0.270 |
Why?
| | Nanoparticles | 2 | 2020 | 325 | 0.270 |
Why?
| | Rats, Inbred SHR | 4 | 2018 | 42 | 0.260 |
Why?
| | Recombination, Genetic | 2 | 2017 | 173 | 0.260 |
Why?
| | Female | 50 | 2022 | 61564 | 0.260 |
Why?
| | Models, Genetic | 5 | 2019 | 595 | 0.260 |
Why?
| | Hypothalamo-Hypophyseal System | 4 | 2017 | 195 | 0.250 |
Why?
| | Genome-Wide Association Study | 2 | 2022 | 1323 | 0.250 |
Why?
| | Heart Transplantation | 2 | 2021 | 671 | 0.250 |
Why?
| | Genotype | 10 | 2022 | 1882 | 0.240 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 159 | 0.240 |
Why?
| | Mice, Inbred C57BL | 11 | 2021 | 4908 | 0.240 |
Why?
| | Gene Expression Regulation | 7 | 2019 | 2445 | 0.230 |
Why?
| | Corneal Injuries | 1 | 2024 | 37 | 0.230 |
Why?
| | Receptors, GABA-A | 2 | 2018 | 89 | 0.220 |
Why?
| | Base Sequence | 6 | 2021 | 2159 | 0.220 |
Why?
| | Mustard Gas | 1 | 2024 | 93 | 0.220 |
Why?
| | Chemical Warfare Agents | 1 | 2024 | 103 | 0.220 |
Why?
| | Rats, Inbred BN | 3 | 2018 | 53 | 0.220 |
Why?
| | Behavior, Addictive | 2 | 2020 | 77 | 0.210 |
Why?
| | Leukopenia | 1 | 2021 | 27 | 0.200 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.200 |
Why?
| | Chromatography, Liquid | 5 | 2024 | 355 | 0.200 |
Why?
| | Magnesium Deficiency | 1 | 2020 | 2 | 0.200 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2021 | 114 | 0.200 |
Why?
| | Complement Activation | 2 | 2021 | 350 | 0.200 |
Why?
| | Breast Neoplasms | 5 | 2019 | 1965 | 0.200 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 79 | 0.190 |
Why?
| | Genome | 3 | 2017 | 277 | 0.190 |
Why?
| | Myocardium | 2 | 2018 | 970 | 0.190 |
Why?
| | Hydroxycholesterols | 1 | 2020 | 3 | 0.190 |
Why?
| | Trace Elements | 1 | 2020 | 46 | 0.190 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2020 | 17 | 0.180 |
Why?
| | Liposomes | 2 | 2019 | 151 | 0.180 |
Why?
| | Algorithms | 3 | 2023 | 1541 | 0.180 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2019 | 21 | 0.180 |
Why?
| | Osteoprotegerin | 3 | 2009 | 23 | 0.180 |
Why?
| | Complement Inactivating Agents | 1 | 2020 | 43 | 0.180 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2019 | 12 | 0.180 |
Why?
| | Signal Transduction | 7 | 2019 | 4709 | 0.180 |
Why?
| | Epithelium, Corneal | 1 | 2019 | 40 | 0.180 |
Why?
| | Pesticides | 1 | 2019 | 47 | 0.180 |
Why?
| | User-Computer Interface | 1 | 2020 | 163 | 0.180 |
Why?
| | Drosophila | 1 | 2020 | 140 | 0.170 |
Why?
| | Anthracenes | 1 | 2019 | 30 | 0.170 |
Why?
| | Reflex, Righting | 2 | 2018 | 10 | 0.170 |
Why?
| | Genetic Markers | 1 | 2020 | 348 | 0.170 |
Why?
| | Protein Corona | 1 | 2019 | 5 | 0.170 |
Why?
| | Mice, Inbred DBA | 5 | 2019 | 174 | 0.170 |
Why?
| | Adult | 28 | 2020 | 31512 | 0.170 |
Why?
| | Acylation | 1 | 2019 | 28 | 0.170 |
Why?
| | Opsonin Proteins | 1 | 2019 | 26 | 0.170 |
Why?
| | Hippocampus | 2 | 2022 | 735 | 0.170 |
Why?
| | Cushing Syndrome | 2 | 2010 | 10 | 0.170 |
Why?
| | Eicosanoids | 1 | 2019 | 57 | 0.170 |
Why?
| | Sex Characteristics | 4 | 2021 | 671 | 0.170 |
Why?
| | Fluorenes | 1 | 2019 | 37 | 0.170 |
Why?
| | Drosophila Proteins | 1 | 2020 | 171 | 0.170 |
Why?
| | Chimera | 1 | 2019 | 60 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 185 | 0.170 |
Why?
| | Gene Expression | 3 | 2014 | 1489 | 0.170 |
Why?
| | Hallucinogens | 1 | 2020 | 74 | 0.170 |
Why?
| | Proteome | 2 | 2020 | 353 | 0.170 |
Why?
| | Unsupervised Machine Learning | 1 | 2018 | 8 | 0.170 |
Why?
| | Steroid 11-beta-Hydroxylase | 1 | 2018 | 3 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 167 | 0.170 |
Why?
| | Middle Aged | 25 | 2021 | 27617 | 0.160 |
Why?
| | Lymphocytes | 1 | 2020 | 347 | 0.160 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 174 | 0.160 |
Why?
| | Antioxidants | 2 | 2019 | 564 | 0.160 |
Why?
| | Immunoglobulins | 1 | 2019 | 154 | 0.160 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 113 | 0.160 |
Why?
| | Whole Genome Sequencing | 1 | 2019 | 113 | 0.160 |
Why?
| | Cell Degranulation | 1 | 2018 | 38 | 0.160 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 102 | 0.160 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 98 | 0.160 |
Why?
| | Biomarkers | 6 | 2020 | 3588 | 0.160 |
Why?
| | Computational Biology | 3 | 2017 | 588 | 0.160 |
Why?
| | Silver | 1 | 2018 | 27 | 0.160 |
Why?
| | Angiography, Digital Subtraction | 1 | 2018 | 46 | 0.160 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 105 | 0.160 |
Why?
| | Receptors, Nicotinic | 1 | 2020 | 295 | 0.160 |
Why?
| | Food Preferences | 2 | 2009 | 119 | 0.160 |
Why?
| | Ferrosoferric Oxide | 1 | 2017 | 26 | 0.160 |
Why?
| | Graft Rejection | 1 | 2021 | 555 | 0.150 |
Why?
| | Interleukin-6 | 3 | 2006 | 688 | 0.150 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2018 | 83 | 0.150 |
Why?
| | Smoking | 2 | 2020 | 1487 | 0.150 |
Why?
| | Hepatitis | 1 | 2017 | 46 | 0.150 |
Why?
| | Dextrans | 1 | 2017 | 74 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 513 | 0.150 |
Why?
| | Mast Cells | 1 | 2018 | 115 | 0.150 |
Why?
| | Web Browser | 1 | 2017 | 16 | 0.150 |
Why?
| | Adipose Tissue, Brown | 1 | 2017 | 71 | 0.150 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 136 | 0.150 |
Why?
| | Multifactorial Inheritance | 1 | 2018 | 143 | 0.150 |
Why?
| | Models, Animal | 1 | 2019 | 363 | 0.150 |
Why?
| | Depressive Disorder, Major | 2 | 2012 | 303 | 0.150 |
Why?
| | Seizures | 1 | 2020 | 345 | 0.150 |
Why?
| | Globins | 2 | 1997 | 22 | 0.150 |
Why?
| | Mitochondria | 2 | 2021 | 786 | 0.150 |
Why?
| | Lod Score | 1 | 2016 | 75 | 0.140 |
Why?
| | Liver Diseases | 1 | 2019 | 282 | 0.140 |
Why?
| | Chromosomes, Mammalian | 1 | 2016 | 26 | 0.140 |
Why?
| | Gene Ontology | 1 | 2016 | 55 | 0.140 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2016 | 9 | 0.140 |
Why?
| | Pain Threshold | 2 | 2010 | 69 | 0.140 |
Why?
| | Cholestasis | 1 | 2019 | 228 | 0.140 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2016 | 16 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 2 | 2015 | 408 | 0.140 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 73 | 0.140 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2016 | 23 | 0.140 |
Why?
| | Anxiety | 1 | 2022 | 845 | 0.140 |
Why?
| | Choice Behavior | 2 | 2014 | 160 | 0.140 |
Why?
| | Doxorubicin | 1 | 2017 | 302 | 0.140 |
Why?
| | von Willebrand Factor | 1 | 2016 | 58 | 0.140 |
Why?
| | Down Syndrome | 1 | 2021 | 356 | 0.140 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2015 | 19 | 0.140 |
Why?
| | Hydrocortisone | 4 | 2012 | 273 | 0.140 |
Why?
| | Complement System Proteins | 1 | 2019 | 294 | 0.140 |
Why?
| | Circadian Rhythm | 2 | 2020 | 401 | 0.140 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 273 | 0.130 |
Why?
| | beta Karyopherins | 1 | 2015 | 8 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2021 | 654 | 0.130 |
Why?
| | Databases, Nucleic Acid | 1 | 2015 | 36 | 0.130 |
Why?
| | Aged | 14 | 2019 | 19657 | 0.130 |
Why?
| | Consensus | 1 | 2018 | 534 | 0.130 |
Why?
| | Dexamethasone | 2 | 2024 | 320 | 0.130 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 81 | 0.130 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 39 | 0.130 |
Why?
| | Darkness | 1 | 2015 | 22 | 0.130 |
Why?
| | Peptides | 1 | 2020 | 879 | 0.130 |
Why?
| | Diet | 3 | 2008 | 1153 | 0.130 |
Why?
| | Immune System | 1 | 2016 | 181 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 401 | 0.130 |
Why?
| | Proteomics | 4 | 2024 | 876 | 0.130 |
Why?
| | Neutrophils | 1 | 2020 | 1233 | 0.120 |
Why?
| | Mammography | 2 | 2006 | 126 | 0.120 |
Why?
| | Anti-HIV Agents | 1 | 2020 | 664 | 0.120 |
Why?
| | Allergens | 1 | 2018 | 424 | 0.120 |
Why?
| | Atherosclerosis | 1 | 2018 | 345 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 280 | 0.120 |
Why?
| | Epithelial Cells | 1 | 2019 | 963 | 0.120 |
Why?
| | Cell Proliferation | 2 | 2018 | 2275 | 0.120 |
Why?
| | Species Specificity | 4 | 2014 | 565 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 226 | 0.120 |
Why?
| | LDL-Receptor Related Proteins | 1 | 2013 | 6 | 0.120 |
Why?
| | Chloride Channels | 1 | 1993 | 35 | 0.120 |
Why?
| | Iron Overload | 1 | 2013 | 10 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 900 | 0.120 |
Why?
| | Cannabis | 1 | 2020 | 382 | 0.120 |
Why?
| | Mice, Knockout | 5 | 2019 | 2680 | 0.120 |
Why?
| | Ultrasonography | 1 | 2018 | 716 | 0.120 |
Why?
| | Apoptosis | 2 | 2020 | 2484 | 0.120 |
Why?
| | Chromosome Mapping | 4 | 2020 | 510 | 0.110 |
Why?
| | Glucocorticoids | 2 | 2009 | 545 | 0.110 |
Why?
| | Genes | 1 | 1993 | 231 | 0.110 |
Why?
| | Database Management Systems | 2 | 2017 | 56 | 0.110 |
Why?
| | Blood Pressure | 1 | 2020 | 1664 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1167 | 0.110 |
Why?
| | Catalase | 2 | 2017 | 123 | 0.110 |
Why?
| | DNA Mutational Analysis | 4 | 2001 | 381 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1323 | 0.100 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2012 | 38 | 0.100 |
Why?
| | Monoamine Oxidase | 1 | 2011 | 25 | 0.100 |
Why?
| | Kidney | 1 | 2019 | 1353 | 0.100 |
Why?
| | Iron | 1 | 2013 | 248 | 0.100 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 366 | 0.100 |
Why?
| | Receptors, GABA | 1 | 2010 | 9 | 0.100 |
Why?
| | Rats, Long-Evans | 2 | 2021 | 105 | 0.100 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2010 | 14 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1390 | 0.100 |
Why?
| | Area Under Curve | 3 | 2019 | 296 | 0.100 |
Why?
| | Hypertension | 1 | 2020 | 1203 | 0.100 |
Why?
| | Pituitary-Adrenal Function Tests | 1 | 2010 | 2 | 0.100 |
Why?
| | Bone Density | 2 | 2012 | 449 | 0.100 |
Why?
| | Disease Models, Animal | 5 | 2019 | 3730 | 0.090 |
Why?
| | Colonic Diseases, Functional | 2 | 2000 | 3 | 0.090 |
Why?
| | RNA, Messenger | 5 | 2018 | 2657 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1206 | 0.090 |
Why?
| | Postmenopause | 1 | 2012 | 305 | 0.090 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 4552 | 0.090 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2010 | 155 | 0.090 |
Why?
| | Morphine | 1 | 2010 | 134 | 0.090 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2009 | 12 | 0.090 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2871 | 0.080 |
Why?
| | Cyclooxygenase 2 | 2 | 2019 | 168 | 0.080 |
Why?
| | RANK Ligand | 1 | 2008 | 28 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2024 | 502 | 0.080 |
Why?
| | Blood Platelets | 1 | 2011 | 369 | 0.080 |
Why?
| | Breeding | 2 | 2014 | 56 | 0.080 |
Why?
| | Receptors, Glucocorticoid | 1 | 2009 | 133 | 0.080 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 94 | 0.080 |
Why?
| | United States | 3 | 2018 | 12555 | 0.080 |
Why?
| | Androgens | 1 | 2009 | 167 | 0.080 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2007 | 54 | 0.080 |
Why?
| | Alanine Transaminase | 2 | 2019 | 152 | 0.080 |
Why?
| | Electronic Mail | 1 | 2007 | 55 | 0.080 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2017 | 152 | 0.080 |
Why?
| | Membrane Proteins | 1 | 1993 | 1055 | 0.080 |
Why?
| | Hepatic Encephalopathy | 1 | 2007 | 22 | 0.070 |
Why?
| | Computer-Assisted Instruction | 1 | 2008 | 66 | 0.070 |
Why?
| | Alcohol Dehydrogenase | 1 | 2006 | 22 | 0.070 |
Why?
| | Adrenal Cortex | 1 | 2006 | 34 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2020 | 940 | 0.070 |
Why?
| | Cytokine Receptor gp130 | 1 | 2006 | 11 | 0.070 |
Why?
| | Superoxide Dismutase | 2 | 2019 | 339 | 0.070 |
Why?
| | HIV Infections | 1 | 2020 | 2459 | 0.070 |
Why?
| | Computer Simulation | 2 | 2023 | 922 | 0.070 |
Why?
| | Receptors, Interleukin-6 | 1 | 2006 | 36 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 111 | 0.070 |
Why?
| | Health Planning Guidelines | 1 | 2006 | 25 | 0.070 |
Why?
| | Brain Chemistry | 2 | 2009 | 119 | 0.070 |
Why?
| | Prednisolone | 1 | 2006 | 76 | 0.070 |
Why?
| | Australia | 1 | 2006 | 212 | 0.070 |
Why?
| | Alleles | 2 | 2019 | 832 | 0.070 |
Why?
| | Up-Regulation | 2 | 2019 | 872 | 0.070 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 253 | 0.070 |
Why?
| | Culture | 1 | 2006 | 129 | 0.070 |
Why?
| | Bone Resorption | 1 | 2006 | 80 | 0.070 |
Why?
| | Program Evaluation | 2 | 2007 | 845 | 0.070 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2006 | 134 | 0.070 |
Why?
| | Muscle Fatigue | 1 | 2006 | 91 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 2851 | 0.070 |
Why?
| | Exercise | 2 | 2006 | 1657 | 0.060 |
Why?
| | Phosphorylation | 2 | 2019 | 1633 | 0.060 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 160 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 381 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2478 | 0.060 |
Why?
| | Health Promotion | 2 | 2008 | 691 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4596 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2021 | 4077 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 473 | 0.060 |
Why?
| | Metabolomics | 2 | 2019 | 550 | 0.060 |
Why?
| | Schools | 1 | 2008 | 411 | 0.060 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2006 | 111 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 1993 | 964 | 0.060 |
Why?
| | Sports | 1 | 2006 | 194 | 0.060 |
Why?
| | Environmental Exposure | 1 | 2008 | 405 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2017 | 3171 | 0.060 |
Why?
| | Albumins | 1 | 2023 | 100 | 0.060 |
Why?
| | Cornea | 1 | 2024 | 117 | 0.060 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 100 | 0.060 |
Why?
| | Analgesics, Opioid | 1 | 2010 | 794 | 0.060 |
Why?
| | Adolescent | 6 | 2019 | 18480 | 0.060 |
Why?
| | Mass Screening | 2 | 2010 | 1052 | 0.060 |
Why?
| | Leptin | 1 | 2004 | 231 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2021 | 12978 | 0.060 |
Why?
| | Rabbits | 1 | 2024 | 780 | 0.050 |
Why?
| | Microarray Analysis | 2 | 2015 | 124 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 940 | 0.050 |
Why?
| | Patient Compliance | 1 | 2006 | 537 | 0.050 |
Why?
| | Health Behavior | 1 | 2007 | 720 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1185 | 0.050 |
Why?
| | Actins | 1 | 2024 | 404 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2004 | 381 | 0.050 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 87 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2006 | 1244 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 827 | 0.050 |
Why?
| | Curriculum | 1 | 2008 | 910 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2006 | 384 | 0.050 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2020 | 4 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2020 | 2071 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 54 | 0.050 |
Why?
| | Risk Factors | 4 | 2019 | 9000 | 0.050 |
Why?
| | Blotting, Western | 2 | 2015 | 1194 | 0.050 |
Why?
| | Time Factors | 4 | 2019 | 6412 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2001 | 268 | 0.050 |
Why?
| | Rats, Inbred F344 | 1 | 2001 | 245 | 0.050 |
Why?
| | Oxysterols | 1 | 2020 | 2 | 0.050 |
Why?
| | Dogs | 1 | 2021 | 371 | 0.050 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2020 | 30 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2021 | 144 | 0.050 |
Why?
| | Magnesium | 1 | 2020 | 150 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2020 | 56 | 0.050 |
Why?
| | Kainic Acid | 1 | 2020 | 32 | 0.050 |
Why?
| | Monte Carlo Method | 1 | 2020 | 146 | 0.050 |
Why?
| | Carbon | 1 | 2021 | 170 | 0.050 |
Why?
| | Indians, North American | 1 | 2006 | 598 | 0.050 |
Why?
| | Italy | 3 | 1997 | 90 | 0.050 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 53 | 0.050 |
Why?
| | Emtricitabine | 1 | 2020 | 146 | 0.050 |
Why?
| | Substance Abuse Detection | 1 | 2020 | 63 | 0.040 |
Why?
| | DNA Primers | 1 | 2001 | 533 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1515 | 0.040 |
Why?
| | Catheterization | 1 | 2000 | 163 | 0.040 |
Why?
| | Protective Agents | 1 | 2019 | 42 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 87 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2021 | 148 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 66 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 95 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2019 | 156 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 155 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 175 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 172 | 0.040 |
Why?
| | Colitis, Ulcerative | 1 | 2000 | 105 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 382 | 0.040 |
Why?
| | Sample Size | 1 | 2019 | 133 | 0.040 |
Why?
| | Group IV Phospholipases A2 | 1 | 2019 | 46 | 0.040 |
Why?
| | Sensation | 1 | 1999 | 43 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 203 | 0.040 |
Why?
| | Dronabinol | 1 | 2020 | 121 | 0.040 |
Why?
| | Protons | 1 | 2019 | 79 | 0.040 |
Why?
| | Metabolic Syndrome | 2 | 2017 | 394 | 0.040 |
Why?
| | Molecular Weight | 1 | 2019 | 343 | 0.040 |
Why?
| | Colorado | 3 | 2020 | 4196 | 0.040 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 229 | 0.040 |
Why?
| | Normal Distribution | 1 | 2018 | 24 | 0.040 |
Why?
| | Sirtuins | 1 | 2019 | 34 | 0.040 |
Why?
| | Receptors, AMPA | 1 | 2020 | 125 | 0.040 |
Why?
| | Caspase 3 | 1 | 2019 | 243 | 0.040 |
Why?
| | Pregnancy | 3 | 2020 | 5690 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 136 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 467 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 159 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 14 | 0.040 |
Why?
| | Cardiovascular Diseases | 2 | 2008 | 1798 | 0.040 |
Why?
| | Metyrapone | 1 | 2018 | 7 | 0.040 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 16 | 0.040 |
Why?
| | Dinitrobenzenes | 1 | 2018 | 6 | 0.040 |
Why?
| | Ribosomes | 1 | 2019 | 142 | 0.040 |
Why?
| | Computer Graphics | 1 | 2018 | 48 | 0.040 |
Why?
| | Fluorescent Dyes | 1 | 2020 | 316 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2018 | 75 | 0.040 |
Why?
| | Receptors, IgE | 1 | 2018 | 40 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 285 | 0.040 |
Why?
| | Sirtuin 3 | 1 | 2019 | 60 | 0.040 |
Why?
| | Abdominal Pain | 1 | 1999 | 133 | 0.040 |
Why?
| | Inflammation | 2 | 2019 | 2566 | 0.040 |
Why?
| | Fetal Development | 1 | 2020 | 250 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1974 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 176 | 0.040 |
Why?
| | Magnetite Nanoparticles | 1 | 2017 | 28 | 0.040 |
Why?
| | Azo Compounds | 1 | 2017 | 25 | 0.040 |
Why?
| | Thioredoxins | 1 | 2017 | 30 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6561 | 0.040 |
Why?
| | Organ Specificity | 1 | 2018 | 278 | 0.040 |
Why?
| | Tuberculosis | 1 | 2020 | 240 | 0.040 |
Why?
| | Heterozygote | 3 | 1994 | 262 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 306 | 0.040 |
Why?
| | Crigler-Najjar Syndrome | 1 | 1997 | 2 | 0.040 |
Why?
| | Glucuronosyltransferase | 1 | 1997 | 9 | 0.040 |
Why?
| | DNA Damage | 1 | 2019 | 357 | 0.040 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 74 | 0.040 |
Why?
| | Protein Structure, Secondary | 1 | 2018 | 338 | 0.040 |
Why?
| | Camptothecin | 1 | 2017 | 100 | 0.040 |
Why?
| | Metal Nanoparticles | 1 | 2018 | 73 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2019 | 828 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 2436 | 0.040 |
Why?
| | Solubility | 2 | 2008 | 235 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 1047 | 0.040 |
Why?
| | Metabolome | 1 | 2019 | 296 | 0.040 |
Why?
| | Exons | 2 | 1997 | 307 | 0.040 |
Why?
| | Prospective Studies | 3 | 2017 | 6471 | 0.040 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 191 | 0.040 |
Why?
| | Lipids | 1 | 2020 | 607 | 0.040 |
Why?
| | Surface Properties | 1 | 2017 | 397 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 180 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2016 | 75 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2018 | 159 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2007 | 321 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 455 | 0.030 |
Why?
| | Lipogenesis | 1 | 2016 | 66 | 0.030 |
Why?
| | Medication Adherence | 1 | 2020 | 556 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 86 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 683 | 0.030 |
Why?
| | Animals, Inbred Strains | 1 | 2015 | 7 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 670 | 0.030 |
Why?
| | Young Adult | 3 | 2019 | 10793 | 0.030 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2015 | 15 | 0.030 |
Why?
| | Genetic Testing | 1 | 1997 | 389 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1720 | 0.030 |
Why?
| | Codon | 2 | 1992 | 89 | 0.030 |
Why?
| | Histones | 1 | 2019 | 552 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 788 | 0.030 |
Why?
| | Glutathione | 1 | 2016 | 324 | 0.030 |
Why?
| | Heart | 1 | 2018 | 631 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 345 | 0.030 |
Why?
| | Autophagy | 1 | 2018 | 315 | 0.030 |
Why?
| | Saliva | 2 | 2006 | 188 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2015 | 180 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 827 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 361 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 513 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 420 | 0.030 |
Why?
| | Triglycerides | 1 | 2016 | 519 | 0.030 |
Why?
| | Chelation Therapy | 1 | 2013 | 9 | 0.030 |
Why?
| | Iron Chelating Agents | 1 | 2013 | 17 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 1636 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1231 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2707 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2017 | 726 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1753 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2010 | 2025 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1975 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2017 | 578 | 0.030 |
Why?
| | Glucose | 1 | 2017 | 953 | 0.030 |
Why?
| | Thalassemia | 1 | 1992 | 7 | 0.030 |
Why?
| | Exome | 1 | 2013 | 220 | 0.030 |
Why?
| | Child | 3 | 2008 | 19129 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2874 | 0.030 |
Why?
| | Placenta | 1 | 2018 | 638 | 0.030 |
Why?
| | Transferrin | 1 | 2011 | 39 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2011 | 53 | 0.030 |
Why?
| | Neurons | 1 | 2020 | 1345 | 0.030 |
Why?
| | Liver Function Tests | 1 | 2011 | 107 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1715 | 0.020 |
Why?
| | DNA | 3 | 1994 | 1388 | 0.020 |
Why?
| | Obesity | 1 | 2004 | 2746 | 0.020 |
Why?
| | Thermosensing | 1 | 2010 | 10 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 473 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 176 | 0.020 |
Why?
| | Software Design | 1 | 2010 | 23 | 0.020 |
Why?
| | Genetics, Behavioral | 1 | 2010 | 43 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2010 | 138 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 86 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 239 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 2011 | 159 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1993 | 288 | 0.020 |
Why?
| | Logistic Models | 2 | 2006 | 1901 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2010 | 81 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5255 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2009 | 6 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 307 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 9 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2010 | 81 | 0.020 |
Why?
| | Blood Proteins | 1 | 2011 | 248 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1781 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 42 | 0.020 |
Why?
| | Corticosterone | 1 | 2010 | 253 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2017 | 9342 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2008 | 59 | 0.020 |
Why?
| | New Mexico | 1 | 2008 | 67 | 0.020 |
Why?
| | Social Marketing | 1 | 2008 | 14 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2008 | 250 | 0.020 |
Why?
| | Rural Health | 1 | 2008 | 72 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 164 | 0.020 |
Why?
| | Pituitary Function Tests | 1 | 2007 | 4 | 0.020 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2007 | 7 | 0.020 |
Why?
| | Sunlight | 1 | 2008 | 60 | 0.020 |
Why?
| | Fruit | 1 | 2008 | 130 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 133 | 0.020 |
Why?
| | Brain Mapping | 1 | 2010 | 532 | 0.020 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2006 | 32 | 0.020 |
Why?
| | Myoglobin | 1 | 2006 | 15 | 0.020 |
Why?
| | Acetaldehyde | 1 | 2006 | 20 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2007 | 66 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2007 | 72 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2006 | 40 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 379 | 0.020 |
Why?
| | Genetic Carrier Screening | 2 | 1997 | 23 | 0.020 |
Why?
| | Osteoclasts | 1 | 2006 | 36 | 0.020 |
Why?
| | Pituitary Gland | 1 | 2007 | 163 | 0.020 |
Why?
| | Electrophysiology | 1 | 2006 | 204 | 0.020 |
Why?
| | Angiography | 1 | 2007 | 185 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 2006 | 33 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2006 | 210 | 0.020 |
Why?
| | Hormones | 1 | 2006 | 135 | 0.020 |
Why?
| | Phosphorus | 1 | 2006 | 84 | 0.020 |
Why?
| | Bone and Bones | 1 | 2008 | 289 | 0.020 |
Why?
| | Reminder Systems | 1 | 2007 | 163 | 0.020 |
Why?
| | Educational Status | 1 | 2008 | 437 | 0.020 |
Why?
| | Educational Measurement | 1 | 2008 | 289 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 290 | 0.020 |
Why?
| | Physical Endurance | 1 | 2006 | 231 | 0.020 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2006 | 192 | 0.020 |
Why?
| | Lactic Acid | 1 | 2006 | 282 | 0.020 |
Why?
| | Electromyography | 1 | 2006 | 326 | 0.020 |
Why?
| | Pedigree | 2 | 1997 | 485 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 58 | 0.020 |
Why?
| | Neoplasms | 1 | 2018 | 2179 | 0.020 |
Why?
| | Risk | 1 | 2007 | 853 | 0.020 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2004 | 91 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2004 | 324 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2004 | 204 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 194 | 0.010 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 683 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1868 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 153 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 416 | 0.010 |
Why?
| | Vitamin D | 1 | 2006 | 354 | 0.010 |
Why?
| | Dietary Fats | 1 | 2004 | 322 | 0.010 |
Why?
| | Odds Ratio | 1 | 2004 | 996 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 3174 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5116 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1223 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 676 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2008 | 762 | 0.010 |
Why?
| | Calcium | 1 | 2006 | 1169 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2006 | 687 | 0.010 |
Why?
| | Viscera | 1 | 1999 | 16 | 0.010 |
Why?
| | Child, Preschool | 2 | 2008 | 9491 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 969 | 0.010 |
Why?
| | Psychological Tests | 1 | 1999 | 129 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 2995 | 0.010 |
Why?
| | Pain Measurement | 1 | 2000 | 469 | 0.010 |
Why?
| | Cytokines | 1 | 2006 | 1900 | 0.010 |
Why?
| | Perception | 1 | 2000 | 314 | 0.010 |
Why?
| | Registries | 1 | 2004 | 1810 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2092 | 0.010 |
Why?
| | Genetics, Population | 1 | 1997 | 207 | 0.010 |
Why?
| | Prenatal Diagnosis | 1 | 1997 | 168 | 0.010 |
Why?
| | Mutation | 2 | 1997 | 3457 | 0.010 |
Why?
| | Homozygote | 1 | 1994 | 190 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2000 | 2674 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 1992 | 28 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 332 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1012 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 4708 | 0.000 |
Why?
| | Infant | 1 | 1997 | 8293 | 0.000 |
Why?
|
|
Saba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|